Denmark Castrate-resistant Prostate Cancer Market Size & Outlook
Related Markets
Denmark castrate-resistant prostate cancer market highlights
- The Denmark castrate-resistant prostate cancer market generated a revenue of USD 174.3 million in 2024 and is expected to reach USD 266.9 million by 2030.
- The Denmark market is expected to grow at a CAGR of 7.3% from 2025 to 2030.
- In terms of segment, hormonal therapy was the largest revenue generating therapy in 2024.
- Immunotherapy is the most lucrative therapy segment registering the fastest growth during the forecast period.
Castrate-resistant prostate cancer market data book summary
| Market revenue in 2024 | USD 174.3 million |
| Market revenue in 2030 | USD 266.9 million |
| Growth rate | 7.3% (CAGR from 2025 to 2030) |
| Largest segment | Hormonal therapy |
| Fastest growing segment | Immunotherapy |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Chemotherapy, Hormonal Therapy, Immunotherapy, Radiotherapy |
| Key market players worldwide | Sanofi SA, Johnson & Johnson, Pfizer Inc, Astellas Pharma Inc, Bayer AG |
Other key industry trends
- In terms of revenue, Denmark accounted for 1.3% of the global castrate-resistant prostate cancer market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany castrate-resistant prostate cancer market is projected to lead the regional market in terms of revenue in 2030.
- France is the fastest growing regional market in Europe and is projected to reach USD 931.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Castrate-resistant Prostate Cancer Market Scope
Castrate-resistant Prostate Cancer Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Astellas Pharma Inc | View profile | 14484 | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 | http://www.astellas.com |
| Bayer AG | View profile | 99723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | https://www.bayer.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
Denmark castrate-resistant prostate cancer market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to castrate-resistant prostate cancer market will help companies and investors design strategic landscapes.
Hormonal therapy was the largest segment with a revenue share of 45.96% in 2024. Horizon Databook has segmented the Denmark castrate-resistant prostate cancer market based on chemotherapy, hormonal therapy, immunotherapy, radiotherapy covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Denmark castrate-resistant prostate cancer market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Denmark castrate-resistant prostate cancer market databook
-
Our clientele includes a mix of castrate-resistant prostate cancer market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Denmark castrate-resistant prostate cancer market, including forecasts for subscribers. This country databook contains high-level insights into Denmark castrate-resistant prostate cancer market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Denmark castrate resistant prostate cancer market size, by therapy, 2018-2030 (US$M)
Denmark Castrate-resistant Prostate Cancer Market Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
